Interactions between nitric oxide and lipid oxidation pathways - Implications for vascular disease

被引:203
作者
O'Donnell, VB
Freeman, BA [1 ]
机构
[1] Univ Alabama Birmingham, Dept Anesthesiol, 946 Tinsley Harrison Tower,619 S 19th St, Birmingham, AL 35233 USA
[2] Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35233 USA
[3] Univ Alabama Birmingham, Dept Mol Genet, Birmingham, AL 35233 USA
[4] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA
[5] Cardiff Univ, Wales heart Res Inst, Cardiff CF4 4XN, S Glam, Wales
关键词
eicosanoid signaling; lipid; nitric oxide; oxygen; free radical;
D O I
10.1161/01.RES.88.1.12
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide ((NO)-N-.) signaling pathways and lipid oxidation reactions are of central importance in both the maintenance of vascular homeostasis and the progression of vascular disease. Because both of these pathways involve free radical species that can also react together at extremely fast rates, convergent interactions between these pathways are expected. Biochemical and cell biology studies have defined multiple interactions of (NO)-N-. with oxidizing lipids that could lead to either vascular protection or potentiation of inflammatory vascular injury. For example, low levels of (NO)-N-. generated by endothelial nitric oxide synthase can terminate propagating lipid radicals and inhibit lipoxygenases, reactions that would be protective, Alternatively, if generated at elevated levels, for example, after inducible nitric oxide synthase expression in inflammation, (NO)-N-. can be converted to prooxidant species, such as peroxynitrite (ONOO-) and nitrogen dioxide ((NO2)-N-.), that can potentiate inflammatory injury to vascular cells, Finally, both enzymatic and nonenzymatic lipid oxidation reactions can influence (NO)-N-. bioactivity by directly scavenging (NO)-N-. or altering the induction and catalytic activity of nitric oxide synthase enzymes. In this review, we summarize the biochemical interactions between (NO)-N-. and lipid oxidation reactions and discuss the recognized and potential roles of these reactions in the vasculature.
引用
收藏
页码:12 / 21
页数:10
相关论文
共 152 条
[1]   COMPARISON OF THE INDUCTION OF CYCLOOXYGENASE AND NITRIC-OXIDE SYNTHASE BY ENDOTOXIN IN ENDOTHELIAL-CELLS AND MACROPHAGES [J].
AKARASEREENONT, P ;
MITCHELL, JA ;
BAKHLE, YS ;
THIEMERMANN, C ;
VANE, JR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 273 (1-2) :121-128
[2]   Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide [J].
AlonsoGalicia, M ;
Drummond, HA ;
Reddy, KK ;
Falck, JR ;
Roman, RJ .
HYPERTENSION, 1997, 29 (01) :320-325
[3]  
Bachmaier K, 1997, CIRCULATION, V96, P585
[4]  
BAILEY JM, 1985, J LIPID RES, V26, P54
[5]   Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages [J].
Baker, CSR ;
Hall, RJC ;
Evans, TJ ;
Pomerance, A ;
Maclouf, J ;
Creminon, C ;
Yacoub, MH ;
Polak, JM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :646-655
[6]   Reciprocal changes in endothelial and inducible nitric oxide synthase expression following carotid angioplasty in the pig [J].
Banning, AP ;
Groves, PH ;
Buttery, LDK ;
Wharton, J ;
Rutherford, RAD ;
Black, P ;
Winkler, F ;
Polak, JM ;
Lewis, MJ ;
Drexler, H .
ATHEROSCLEROSIS, 1999, 145 (01) :17-32
[7]   Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbits [J].
Behr, D ;
Rupin, A ;
Fabiani, JN ;
Verbeuren, TJ .
ATHEROSCLEROSIS, 1999, 142 (02) :335-344
[8]   Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice [J].
Bleich, D ;
Chen, SY ;
Zipser, B ;
Sun, DX ;
Funk, CD ;
Nadler, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (10) :1431-1436
[9]   Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production [J].
Bouloumie, A ;
Bauersachs, J ;
Linz, W ;
Scholkens, BA ;
Wiemer, G ;
Fleming, I ;
Busse, R .
HYPERTENSION, 1997, 30 (04) :934-941
[10]  
BRUNE B, 1991, MOL PHARMACOL, V39, P671